oottawa heart conferences 2016ttawa heart …...ottawa heart conferences 2016 i 4th annual ottawa...

OTTAWA HEART CONFERENCES 2016

i

4th Annual Ottawa HeartResearch Conference

(June 2–3)Steadying the Future of Atrial Fibrillation

Ottawa Heart Conferences 2016Ottawa Heart Conferences 2016Ottawa Heart Conferences 2016

JUNE 2–4, 2016SHAW CENTRE, OTTAWA

&

EASTERN ONTARI O

CARDIOVASCULARSUMMIT

2016

19th International Toronto-Ottawa Heart Summit (June 3–4)

In partnership with theEastern Ontario Cardiovascular Summit XV

The Shaw Centre, 55 Colonel By Drive, Ottawa | www.ottawaheart.ca/ohc2016

19th International Toronto-Ottawa Heart Summit (June 3–4)

In partnership with theEastern OntarioCardiovascular Summit XV

JUNE 2–4, 2016SHAW CENTRE, OTTAWA


ii

Conference Partners

EASTERN ONTARI O

CARDIOVASCULARSUMMIT

2016

SponsorsAppreciation is expressed to the following in support of the Ottawa Heart Conferences 2016:

PLATINUM PATRONS

GOLD PATRONS

SUPPORTERS

Heart & Stroke Richard Lewar Centre of Excellence in Cardiovascular Research

4th

ANNUAL OTTAWA HEART RESEARCH CONFERENCE


1

Contents

Welcome Message . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Steering Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Program Agendas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Program Directors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Faculty Biographies (OHRC) . . . . . . . . . . . . . . . . . . . . . . 13

Faculty Biographies (TOHS & EOCS) . . . . . . . . . . . . . . . . . 27

Faculty Disclosures (OHRC) . . . . . . . . . . . . . . . . . . . . . . 42

Faculty Disclosures (TOHS & EOCS) . . . . . . . . . . . . . . . . . 43

Accreditation Statement . . . . . . . . . . . . . . . . . . . . . . . . 45


2

Welcome Message

Dear Everyone,

The only Constant in Medicine is the Need for Change.

The pace of change in medicine has accelerated in recent times because of our rapidly evolving patient demographics, dramatic system changes, new quality-based funding in Ontario, and research and innovation pushing the frontiers of knowledge.

To integrate the latest research, innovations in guidelines and tools, with the evolving practice landscape, we have partnered three major cardiovascular conferences this year. We are delighted that the joint steering committee has put together a superb program and welcome you to join us at the Shaw Centre Ottawa.

On June 2nd and 3rd, the 4th Annual Ottawa Heart Research Conference will feature state of art advances in research, treatment, and prevention of atrial fi brillation (AF). The afternoon of June 3rd and on June 4th, The 19th Toronto Ottawa Heart Summit, in partnership with the Eastern Ontario Cardiovascular Summit XV, will bring together the most exciting advances in cardiovascular disease and related multidisciplinary conditions, from treatment to prevention, and innovation to application.

This year’s meeting will off er the opportunity for all of our colleagues to come together with the goals to bring innovation, evidence, and experience to the frontline of patient care. The 2016 program features the best quality faculty, the latest topics, together with an engaged audience to provide a rich opportunity for the exchange of ideas, conduct discussions, and a debate to maximize interaction. There have been important advances in these special areas, and we are delighted to provide this unique opportunity for the faculty, health providers, trainees, and health systems decision makers to engage the high-calibre international experts in bringing research to clinical applications.

We are grateful to our perennial conference sponsors for their unconditional support. We extend to you the heartiest welcome to Ottawa, and we look forward to your active participation and suggestions for even more exciting future meetings!

Sincerely,

David Birnie, MD Michael Farkouh, MD

Michael Froeschl, MD Peter Liu, MD


3

Steering Committee

Overall conference chair & chair

of Toronto-Ottawa Heart Summit

(TOHS) subcommittee:

Dr. Peter Liu

Chief Scientifi c Offi cer and Vice President of Research, University of Ottawa Heart Institute

Ottawa Heart Research Confer-

ence (OHRC) subcommittee chair:

Dr. David Birnie

Staff Cardiac Electrophysiologist;Director of the Arrhythmia Services;Director of Clinical Research, Division of Cardiology, University of Ottawa Heart Institute; Associate Professor, University of Ottawa

Toronto Ottawa Heart Summit

subcommittee co-chair:

Dr. Michael Farkouh

Peter Munk Chair in Multinational Clinical Trials; Director, Heart and Stroke Richard Lewar Centre of Excellence; Professor of Medicine, University of Toronto

Eastern Ontario Cardiovascular

Summit (EOCS) chair:

Dr. Michael Froeschl

Interventional Cardiologist, University of Ottawa Heart Institute;Assistant Professor, University of Ottawa

Other steering committee

members:

Dr. Peter Backx (OHRC)Senior Scientist, York University

Dr. Mark Fraser (OHRC/TOHS/EOCS)Fellow of the College of Family Physicians; Active Staff at the Queensway Carleton Hospital;Co-Lead Physician of the West Carleton Family Health

Dr. Bradley Strauss (TOHS) Senior Scientist, Sunnybrook Research Institute; Professor, Department of Medicine,University of Toronto

Dr. Anthony Tang (OHRC)Staff Electrophysiologist;Chair of Cardiovascular Population Health, London Health Science Centre; Scientifi c Director, Canadian Arrhythmia Network (CANet);Professor of Medicine, University of Western Ontario

Dr. Atul Verma (TOHS)Staff Electrophysiologist, York Clinical Cardiology and Metabolism, Southlake Regional Health Centre


4

Pro

gram

Age

nda

Ottawa Heart Research Conference (OHRC):

Steadying the Future of Atrial Fibrillation

Thursday, June 2nd (Day 1)

7:00 am Registration and Breakfast

8:00 am Welcome MessageDrs. David Birnie and Thierry Mesana

8:15–9:35 am Session 1: Exercise, Lifestyle, Obesity, Primary Prevention of Atrial Fibrillation Chair: Dr. Calum Redpath

8:15 am Basic Science Insights into Exercise, Lifestyle, Obesity, Primary Prevention of Atrial FibrillationDr. Peter Backx, York University

8:35 am Aggressive Risk Factor Modifi cation to Reduce Atrial Fibrillation: Is the Evidence Conclusive?Dr. Ratika Parkash, Dalhousie University

8:55 am Can Exercise Improve Quality of Life in Patients with Permanent Atrial Fibrillation?Dr. Jennifer Reed, University of Ottawa Heart Institute

9:15 am Panel Discussion

9:35–10:55 am Session 2: Rotors and Atrial Fibrillation/Atrial Remodeling Chair: Dr. Pablo Nery

9:35 am The Atrial Remodeling Determinants of Rotor DynamicsDr. Stanley Nattel, Montreal Heart Institute

9:55 am Initiation and Maintenance of Rotors in Atrial FibrillationDr. José Jalife, University of Michigan

10:15 am Mapping and Ablating Rotors in the Electrophysiology Lab: Where are we and Where are we Going?Dr. Damian Redfearn, Queen’s University


10:55 am Health Break

11:15–12:35 pm

Session 3: Genetics/Biomarkers/miRNA Chair: Dr. Robert Lemery

11:15 am Personalizing Care for Atrial Fibrillation: The Promise of Gene-Guided StrategiesDr. Jason Roberts, University of Western Ontario

11:35 am Novel Approaches to Preventing Atrial Fibrillation ProgressionDr. Stanley Nattel, Montreal Heart Institute


5

11:55 am Early Detection of the Atrial Fibrillation SubstrateDr. Peter Liu, University of Ottawa Heart Institute

12:15 pm Panel Discussion

12:35 pm Lunch

1:35–2:35 pm Professor Martin Green Keynote Lecture:Stroke Risk Reduction in Atrial Fibrillation: Past, Present and Future Professor Gregory Lip, University of Birmingham

2:35 pm Health Break

2:50–4:00 pm Session 4: Key Clinical Research Directions in Atrial Fibrillation Chair: Dr. Martin Green

2:50 pm Ten Most Important Atrial Fibrillation Related Stroke Clinical Research Questions in 2016: C-SPIN and MoreDr. Jeff Healey, McMaster University

3:10 pm CANet: Canada’s Opportunity to Become World Leader in Atrial Fibrillation Clinical ResearchDr. Anthony Tang, University of Western Ontario


3:50 pm Day 1 Concluding RemarksDr. David Birnie

4:00 pm Adjournment

OHRC/Toronto-Ottawa Heart Summit (TOHS) &Eastern Ontario Cardiovascular Summit (EOCS)

Friday, June 3rd (Day 2)


8:00 am Offi cial Welcome and IntroductionDrs. Peter Liu and Michael Farkouh

8:15–9:35 am Session 1: Ablation for Atrial Fibrillation (Who, How and When) Chair: Dr. David Birnie

8:15 am Current Perspectives and Future DirectionsDr. Hugh Calkins, Johns Hopkins Hospital

8:45 am Ablation of Persistent Atrial FibrillationDr. Atul Verma, Southlake Regional Health Centre


Program Agenda


6

9:35–10:55 am Session 2: Stroke Reduction in Atrial Fibrillation: Update for the Clinician

Chair: Dr. David Birnie

9:35 am Recent Updates from the Canadian GuidelinesDr. Allan Skanes, University of Western Ontario

10:05 am Controversial Areas in Atrial FibrillationDr. Hugh Calkins, Johns Hopkins Hospital



TOHS & EOCS

11:15–12:55

pm

Session 3: Heart Failure Chair: Dr. Peter Liu

11:15 am Role of LCZ696 in Contemporary Treatment of HFrEF and HFpEF: Present and FutureDr. Kirkwood Adams, University of North Carolina at Chapel Hill

11:35 am New Roles of ARNI or LCZ696 in HFpEF or Post MI Remodeling and BeyondDr. Peter Liu, University of Ottawa Heart Institute

11:55 am Guiding Treatment of Heart Failure with BiomarkersDr. Alan Maisel, VA San Diego Healthcare System

12:15 pm Personalizing Therapy for Heart Failure—Heart Rate as a Biomarker?Dr. Peter Liu, University of Ottawa Heart Institute


12:55 pm Lunch

2:00 pm Keynote Lecture: End-of-life Care in Cardiac PatientsDr. Christopher Simpson, Queen’s University

2:30–4:10 pm Session 4: Acute Coronary Syndrome & Cardiac Critical Care Chair: Dr. Michael Froeschl

2:30 pm What to Know about CTODr. Bradley Strauss, Sunnybrook Health Sciences Centre

2:50 pm Antiplatelet Therapy after Percutaneous Coronary Intervention—Understanding the ACC/AHA GuidelinesDr. Derek So, University of Ottawa Heart Institute

3:10 pm Critical Appraisal of Target Temperature Management in Out-of-hospital Cardiac ArrestDr. Michel Le May, University of Ottawa Heart Institute

Pro

gram

Age

nda


7

Program Agenda

3:30 pm Chest Pain Syndromes and Patient EngagementDr. Michael Froeschl, University of Ottawa Heart Institute

3:50 pm Active Learning Q & A with Panel

4:10 pm Health Break

4:25–6:00 pm Session 5: Recent Advances in Cardiovascular Management Chair: Dr. Thierry Mesana

4:25 pm TAVI Update and ImplicationsDr. Thierry Mesana, University of Ottawa Heart Institute

4:45 pm Aortic Diseases – Who, When, What, How?Dr. Munir Boodhwani, University of Ottawa Heart Institute

5:05 pm Promising Diagnostic to Direct Heart Failure Management: The IMAGE-Heart Failure TrialDr. Robert Beanlands, University of Ottawa Heart Institute


5:45 pm Adjournment

Saturday, June 4th (Day 3)


8:00 am Offi cial Welcome and IntroductionDrs. Peter Liu and Michael Farkouh

8:10 am Keynote Lecture: Primary Care and Use of High Sensitivity Troponins–Here they Come!Dr. Alan Maisel, VA San Diego Healthcare System

8:30–9:50 am Session 6: Diabetes Chair: Dr. Michael Farkouh

8:30 am SGLT2 Inhibitors and CVD in Diabetes: The EMPA-REG OUTCOME TrialDr. Bernard Zinman, University of Toronto

8:50 am Liraglutide, a New LEADER in Type 2 DM Management?Dr. Michael Farkouh, University of Toronto

9:10 am Renal Implications of Diabetes TreatmentDr. Kim Connelly, St. Michael’s Hospital

9:30 am Active Learning Q & A with Panel


10:20–11:50

am

Session 7: Atherosclerosis Chair: Dr. Jacob Udell

10:20 am Can we Pacify Atherosclerosis by Novel Anti-infl ammatory Approaches?Dr. Jacob Udell, University of Toronto


8

10:40 –11:20

am

DEBATE on PCSK9: All High Risk Patients with Residual Elevation of LDL Should be on PCSK9 InhibitorsPro—Dr. John Mancini, University of British ColumbiaCon—Dr. Ruth McPherson, University of Ottawa Heart Institute

11:20 –11:40

am

RebuttalDr. John Mancini, University of British ColumbiaDr. Ruth McPherson, University of Ottawa Heart Institute

11:40 am Active Learning Q & A with Panel

12:00 pm Lunch

1:00–2:20

pm

Session 8: Risk Intervention Chair: Dr. Ruth McPherson

1:00 pm State-of-the-Art in Hypertention Control: Can we still SPRINT after HOPE-3?Dr. Sheldon Tobe, Sunnybrook Health Sciences Centre

1:20 pm Exercise Interventions for Patients with Heart Disease: What’s New? What’s Promising?Dr. Robert Reid, University of Ottawa Heart Institute

1:40 pm Early Atherosclerosis Imaging: Detection and Risk InterpretationDr. Girish Dwivedi, University of Ottawa Heart Institute


2:20–3:20

pm

Session 9: Challenges in Managing the Geriatric Population Chair: Dr. Sheldon Tobe

2:20 pm Frailty as a New Risk Factor for Chronic Cardiovascular Risk?Dr. Sheldon Tobe, Sunnybrook Health Sciences Centre

2:40 pm Geripardy! The Answer is: “What is Geriatrics?”Dr. Allen Huang, University of Ottawa


3:20 pm Adjournment and light refreshments

Pro

gram

Age

nda


9

Dr. David Birnie received his medical degree (MB ChB) from Glasgow University in 1990. After completion

of Internal Medical training at Aberdeen University he gained his MRCP (UK) in 1993. He spent three

years as a cardiology research fellow at Glasgow University from 1993 studying the immunology of

atherosclerosis and was awarded his PhD equivalent (MD) in 1996. Between 1996 and 2001 he undertook

cardiology training at Glasgow University and received his Certifi cate of Completion of Specialist

Cardiology Training in 2001. In addition he spent a year in 1999-2000 as a Cardiac Electrophysiology Fellow

at the University of Ottawa Heart Institute. Dr. Birnie was recruited to the University of Ottawa Heart

Institute in 2002 as staff cardiac electrophysiologist and clinician investigator.

Dr. Birnie is a founding and current member of the Canadian Heart Rhythm Society Research Committee.

He is chair of the fi rst international guidelines for the diagnosis and management of cardiac sarcoidosis. He

currently sits on both Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation peer

review panels.

Since 2013, Dr. Birnie, as principal investigator, has been awarded grants from the Heart and Stroke

Foundation of Canada and is a recipient of the Heart and Stroke Foundation Ontario (HSFO) Mid Career

Investigator Award, where his application was ranked no.1 in the competition. He plays a leading role as

Co-Principal Investigator on the CIHR Canadian Atrial Fibrillation Stroke Prevention Network and in the

NCE Canadian Arrhythmia Network (CANet). Dr. Birnie has previously been funded by the British Heart

Foundation, HSFC, CIHR and the JP Bickell Foundation.

Dr. Birnie is the Director of the Arrhythmia Service at UOHI. His clinical focus is on all aspects of cardiac

electrophysiology including arrhythmia pharmacotherapy and radiofrequency ablation of simple and

complex arrhythmias including atrial fi brillation. He also has a major clinical interest in all aspects of

implantation and follow-up of device therapy for arrhythmias. This includes pacemakers, implantable

cardioverter defi brillators (ICD) and cardiac resynchronization therapy (CRT).

Dr. Birnie’s major ongoing research interests are selection and optimization of CRT for heart failure

patients, investigating optimal strategies for stroke reduction around device surgery and cardiac

sarcoidosis.

David Birnie, MB, ChB, MRCP, MD

Clinician Investigator, Staff Cardiac Electrophysiologist,

Chair in Electrophysiology Leadership;

Director, Arrhythmia Service;

Director, Clinical Research, Division of Cardiology,

University of Ottawa Heart Institute;

Mid-Career Investigator, Heart and Stroke Foundation;

Associate Professor, Division of Cardiology, Department of Medicine

University of Ottawa

Program Directors


10

Dr. Michael E. Farkouh is a graduate of the Schulich School of Medicine at Western University. Dr. Farkouh

completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of

Medicine at Mount Sinai New York respectively and holds an MSc in Clinical Epidemiology from McMaster

University.

Prior to his current appointments, Dr. Farkouh served as the founding director of the Mount Sinai

Cardiovascular Clinical Trials Unit in New York City. He has published over 200 papers largely on acute

coronary syndromes and cardiovascular prevention. He has mentored numerous international residents

and fellows and is active in teaching clinical research methodology.

Dr. Farkouh is internationally known for his work on the management of acute coronary syndromes in the

emergency room. He has a special interest and expertise in the fi eld of cardiovascular disease in diabetic

patients. He is currently the project offi cer for numerous clinical trials on questions related to diabetes and

heart disease including the NIH-sponsored FREEDOM trial and coordinates clinical studies in Grenada and

Colombia. He chairs the committee on diabetes and heart disease at the Banting and Best Centre and at

the University of Toronto.

Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the

Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award from the International

Academy of Cardiology.

Michael E. Farkouh, MD, FRCPC, MSc, FACC, FAHA

Peter Munk Chair in Multinational Clinical Trials, University Health Network;

Director of the Heart and Stroke / Richard Lewar Centre of Excellence in

Cardiovascular Research;

Professor and Vice-Chair, Research, Department of Medicine, University of

Toronto


11

Dr. Froeschl received his bachelor’s degree from Harvard University and his medical degree from McGill

University. His clinical training includes three years at the University of Toronto in internal medicine

and four years at the University of Ottawa Heart Institute—three in adult cardiology and a fourth in

interventional cardiology. He joined the Division of Cardiology at the University of Ottawa in 2006. Dr.

Froeschl’s chief academic interest is medical education. In 2011, he completed a master’s degree in

health professions education at Maastricht University in the Netherlands, supported by the Royal College

of Physicians and Surgeons of Canada Fellowship for Studies in Medical Education. He was appointed

Director of the Adult Cardiology Residency Training Program at the University of Ottawa in 2013, and in

2015, he was appointed Director of Education for the Division of Cardiology.

Michael Froeschl, MD, MSc, FRCPC, FACC

Director of Education, Division of Cardiology, University of Ottawa


12

Dr. Liu joined the Heart Institute as the Scientifi c Director in 2012. He received his M.D. and completed his

postgraduate training in Internal Medicine and Cardiology at University of Toronto and Harvard Medical

School.

Formerly, as the inaugural Director of the Heart & Stroke/Richard Lewar Centre of Excellence at the

University of Toronto, Dr. Liu successfully fostered collaboration amongst researchers from various

institutions, while increasing the impact of publications. Subsequently as Scientifi c Director of the

Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research (CIHR), Dr. Liu

launched national networks in imaging, clinical trials and knowledge translation and fostered national

and international research networks. Dr. Liu has designed the Ottawa region cardiovascular research

strategy (ORACLE) and is implementing it in stages. Dr. Liu also directs several large-scale national and

international research programs.

Dr. Liu has been recognized with numerous awards, including both the Research Achievement Award and

the Life Time Achievement Award of the Canadian Cardiovascular Society, the Rick Gallop Award of the

Heart & Stroke Foundation, and the Institute of Circulatory & Respiratory Health Distinguished Lecture

Award of CIHR, and the Margolese Award from UBC, amongst others.

Well known for his contributions to heart failure and cardiac infl ammation research, Dr. Liu discovered

how viruses can enter the myocardium and trigger infl ammation, and how innate and acquired immunity

contribute to cardiac remodeling and heart failure progression following injury. His laboratory currently

focuses on innovative proteomic biomarkers to detect early and personalize treatment for cardiac diseases,

and elucidate novel mechanisms of disease.

Dr. Liu is also interested in knowledge translation, having harmonized and simplifi ed the major national

guidelines using a novel evidence-based consensus approach (C-CHANGE program), and fi nding ways to

maximize knowledge translation globally using innovative technologies.

Peter Liu, MD, FRCPC

Chief Scientifi c Offi cer/ Vice President , Research


Director, Cardiac Function Laboratory


Professor, Faculty of Medicine, University of Ottawa;

Professor, Faculty of Medicine, University of Toronto.


13

Faculty Biographies (OHRC)

Dr. Backx bio ...

Peter Backx, PhD

Senior Scientist, York University

Dr. Hugh Calkins is an internationally recognized expert on catheter ablation, atrial fi brillation, syncope,

arrhythmogenic right ventricular dysplasia (ARVD) and arrhythmia management.

Dr. Calkins attended Williams College and Harvard Medical School before training in medicine at

Massachusetts General Hospital. He received his cardiology training at Johns Hopkins. His fi rst faculty

position was at the University of Michigan, where he directed the Pacemaker Service, and he returned to

Johns Hopkins as director of the Arrhythmia Service in 1992.

Dr. Calkins is an Associate Editor of the Journal of Cardiovascular Electrophysiology and is on the editorial

board of many other cardiology journals. He is a former member of the American Board of Internal

Medicine Electrophysiology Boards Test Writing Committee. Dr. Calkins is a fellow of the American College

of Cardiology, the American Heart Association and the Heart Rhythm Society. He led a 44-member

Hugh Calkins, MD

Professor of Cardiology

Director of Electrophysiology

Nicholas J. Fortuin MD, Professor of Cardiology

Johns Hopkins Medical Institutions

Past President, The Heart Rhythm Society

Professor of Medicine


14

Dr. Green graduated from the Faculty of Medicine at the University of Toronto in 1975, at which time he

was awarded the KJR Wightman Award in Internal Medicine and the Cody Silver Medal. He trained in

Internal Medicine at the University of Ottawa, becoming a Fellow of the Royal College of Physicians and

Surgeons of Canada (FRCPC) in Medicine and in Cardiology.

He then travelled to Maastricht, the Netherlands, to further his training in Cardiac Electrophysiology under

the direction of Professor Hein J. J. Wellens as a Fellow of the Medical Research Council of Canada. Dr.

Green returned to Ottawa to start the Arrhythmia Service in 1983.

Martin Green, MD, FRCPC

Cardiologist, University of Ottawa Heart Institute;

Professor, Department of Medicine, University of Ottawa

international task force whose 2012 Expert Consensus Statement gave recommendations for treatment

and research of atrial fi brillation. Dr Calkins is a past president of the Heart Rhythm Society and was

elected to be a member of the Miler Coulsen Academy of Clinical Excellence in 2014.

Dr. Calkins has published more than 500 articles and book chapters on a large variety of cardiac

arrhythmias. His research has focused predominantly on catheter ablation, atrial fi brillation, syncope, and

arrhythmogenic right ventricular dysplasia. Dr. Calkins has also written extensively on most aspects of

heart rhythm disorders and their treatment.

Robert Lemery, MD

Staff Electrophysiologist,

University of Ottawa Heart Institute


15

Jeff Healey is the director of arrhythmia services and associate professor of medicine at McMaster

University. He is also a clinical trialist, and member of the Population Health Research Institute. Dr. Healey

completed his clinical training in cardiology and electrophysiology at the University of Ottawa Heart

Institute and completed his Master’s degree in health research methodology at McMaster University.

Currently, Dr. Healey’s clinically activities involve both catheter ablation and pacemaker/ICD implantation.

His research involves the conduct of randomized clinical trials and large registries in the fi elds of cardiac

arrhythmias and cardiac devices. His area of research focus is studying the eff ect of risk factors, and risk

factor modifi cation on the development of atrial fi brillation and its complications, such as stroke.

Dr. Healey was the lead author of the ASSERT trial, which was published in the New England Journal

of Medicine in 2012 and demonstrated the increased stroke risk associated with sub-clinical atrial

fi brillation detected by pacemakers. Thomson-Reuters recognized ASSERT as the 38th most-cited scientifi c

publication in 2012 (#16 in Medicine).

Dr. Healey has published over 280 manuscripts and abstracts, including 60 manuscripts in the past 2

years (24 as fi rst or last author). Dr. Healey has received numerous grants from the Canadian Institutes of

Health Research, the Heart and Stroke Foundation and from industry. He is the co-chair of the Canadian

Cardiovascular Society’s Atrial Fibrillation Guidelines Committee, co-chair of the CCS Guidelines for

Perioperative management of pacemakers and defi brillators and past chair of the Cardiac Care Network of

Ontario’s Heart Rhythm Working group.

Dr. Healey is the principal investigator and chair of the Canadian Stroke Prevention Intervention Network

(C-SPIN), a ten-year network grant funded by the Canadian Institutes of Health Research, The Heart and

Stroke Foundation of Canada and Industry. CSPIN will conduct a series of clinical trials related to atrial

fi brillation and stroke prevention and will also support the development of new Canadian researchers in

this fi eld.

Jeff Healey, MD, FRCPC

Principal Investigator, Arrhythmia Program,

Population Health Research Institute;

Associate Professor, McMaster University;

Director of Arrhythmia Services, Hamilton Health Sciences;

Chair, Canadian Stroke Prevention Intervention Network (C-SPIN)


16

Dr. Jalife completed his MD at the Universidad Nacional Autónoma de México in 1972. After clinical

training in Spain, he moved to the United States to work as a postdoctoral fellow at the Upstate Medical

Center in Syracuse, NY, and the Masonic Medical Research Laboratory in Utica, NY. He joined the

Department of Pharmacology, Upstate Medical University, as a member of the faculty in 1980 and became

its Chairman in 1988. In January of 2008, he was recruited by the University of Michigan to his present

position as Professor of Internal Medicine and the Cyrus and Jane Farrehi Professor of Cardiovascular

Research and Professor of Molecular & Integrative Physiology.

Dr. Jalife enjoys an international reputation as a leader in the study of cardiac arrhythmias. His work has

increased the understanding of the fundamental mechanisms of atrial fi brillation, ventricular tachycardia/

fi brillation and sudden cardiac death. He has published more than 320 original papers and review articles,

and has edited/authored fi fteen books, including the internationally acclaimed Cardiac Electrophysiology:

From Cell to Bedside, now in its sixth edition. Dr. Jalife has served the US National Institutes of Health

in many capacities, including past membership in Research Committee-A, the Cardiology Advisory

Committee, the Cardiovascular Study Section, (CVA), and the ESTA Study Section of the National Heart

Lung and Blood Institute. He has also been a member of multiple site visit committees and ad-hoc review

committees of the NHLBI and the American Heart Association.

Throughout his career Dr. Jalife has trained more than 100 scientists for research careers at nearly all

educational levels, including pre-doctoral fellow for PhD degrees, medical student, post-doctoral trainees,

medical residents and clinical fellows. In 2001 Dr. Jalife was awarded the Distinguished Scientist Award

of the American College of Cardiology. Other accolades include the Distinguished Scientist Award of the

Heart Rhythm Society, the Lucian Award for Research in Circulatory Diseases from McGill University, the

President’s Award for Research at SUNY Upstate Medical University, the Professor Pierre Rijlant Award

from the Académie Royale de Médecine de Belgique in Brussels, Belgium, the State University of New York

Chancellor’s Award for Excellence in Scholarship and Creative Activities, the Mirowski Award of Excellence

in the fi eld of Clinical Cardiology and Electrophysiology and the Arthur C. Guyton Distinguished Lecturer

ward from the Association of Chairs of Departments of Physiology. Dr. Jalife is an honorary member of

the Mexican National Academy of Medicine, Fellow of the American Heart Association, Fellow of the

Heart Rhythm Society and member of the Association the American Association of Physicians; between

2010 and 2012 he served as President of the Cardiac Electrophysiology Society. In 2015 he was awarded a

Doctor Honoris Causa by the University of Valencia in Spain.

José Jalife, MD

Cyrus and Jane Farrehi Professor of Cardiovascular Research;

Professor of internal medicine and molecular and integrative physiology,

University of Michigan Medical School;

Co-director of the University of Michigan Center for Arrhythmia Research


17

Professor Lip is a member of the European Heart Rhythm Association (EHRA) and Chairs its scientifi c

documents committee (2013-). He serves on the board of the Working Group on Thrombosis of

the European Society of Cardiology (ESC). He is a member of the Working Group on Cardiovascular

Pharmacology of the ESC, and is also a member of the European Association of Percutaneous Coronary

Revascularisation.

Professor Lip has acted as Clinical Adviser for the UK National Institute for Health & Clinical Excellence

(NICE) guidelines on atrial fi brillation (AF) management (2006), and part of the Guideline Development

Group for the 2014 NICE guidelines on AF. He was also on the writing committee for the 8th American

College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as

various guidelines and/or position statements from EHRA including the EHRA statement on defi ning

endpoints for AF management and EHRA guidelines for antithrombotic therapy during ablation.

He has acted as Chair for task forces, writing a EHRA/Working Group on Thrombosis Position Statement on

Bleeding Risks in Atrial Fibrillation Patients (2011), as well as joint consensus document of the ESC Heart

Failure Association and Working Group Thrombosis on Thromboembolism and Antithrombotic Therapy for

Heart Failure in Sinus Rhythm (2012).

Professor Lip was Chairman of the Task Force which developed and launched a new EHRA patient

information webpage (www.afi bmatters.org), launched June 2013.

He was also on the writing committee of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC

Focused Update Guidelines on Atrial Fibrillation, and the 2012 ESC Guidelines on Heart Failure. He was

Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012).

Professor Lip has acted as Senior Editor for major international textbooks [eg, Lip GYH, Hall JE (eds)

Comprehensive Hypertension. Mosby 2007] and Section Editor on hypertension (eg, Crawford, DiMarco,

PaulusCardiology, now in 3rd edition), as well as contributed to major textbooks [eg, the European

Textbook of Cardiovascular Medicine (chapter on atrial fi brillation that serves as the core curriculum for

ESC cardiology trainees), and Crawford’s Cardiology textbook chapter on atrial fi brillation, etc.

Professor Lip is involved at the senior editorial level for major international journals, including Thrombosis

& Haemostasis (Editor-in-Chief, Clinical Studies - Impact Factor 6.094); Europace (Associate Editor);

andCirculation (Guest Editor). Under his editorship, Thrombosis and Haemostasis was winner of the

Thomson Reuters ScholarOne Journal Triathlon, an international award given to the publication which

shows effi ciency, longevity and validation of submissions (issued December 2013)

Gregory YH Lip, MD, FRCPC, DFM, FACC, FESC

Institute of Cardiovascular Sciences

Consultant Cardiologist and Professor of Cardiovascular Medicine

Director – Haemostasis Thrombosis & Vascular Biology Unit

University of Birmingham Centre for Cardiovascular Sciences


18

Professor GYH Lip MD has research interests in atrial fi brillation, hypertension, heart failure, thrombosis

and antithrombotic therapy, and ethnic diff erences in vascular disease. In addition, he has a major interest

into the psychophysiology and understanding of the disease process in cardiovascular disease (including

atrial fi brillation), as well as physician and patient perceptions of antithrombotic management strategies.

Finally, he leads a laboratory-based research group into thrombosis and vascular biology in cardiovascular

disease and stroke.

A native of France, Dr. Mesana is recognized as one of the leading heart valve surgeons in the world. He

received his medical degree at the Université de la Méditerranée, Marseille, France, where he trained

in thoracic and cardiovascular surgery. He received his PhD in biophysics and biomechanics at the same

university after extensive experimental work on artifi cial hearts and ventricular assist devices.

Dr. Mesana’s specialty interests include adult cardiac surgery, valvular heart disease, mitral valve

repair, surgery of thoracic aorta and aortic dissection, and surgery of heart failure, including heart

transplantation, ventricular assist devices, and cardiomyoplasty.

He is recognized as one of the world’s leading heart valve surgeons, with specifi c emphasis in mitral

valve repair. His leadership led to signifi cant changes in the Division of Cardiac Surgery at the University

of Ottawa Heart Institute, with the rapid development of complex and innovative mitral valve repair

techniques in degenerative or ischemic disease, and the development of surgical ablation for atrial

fi brillation.

He has also strongly supported and contributed to research in myocardial regeneration and endothelial

stem cells. His group in Ottawa has published extensive studies related either to basic research in

angiogenesis or to clinical research into long-term follow-up of patients with heart valve prostheses.

These include studies on aortic prosthesis mismatch, predictors of long-term outcome, such as stroke,

heart failure, mitral valve prosthetic mismatch, tissue valve durability, and re-operation rates.

Dr. Mesana has been directly involved in most of the research projects in the Division of Cardiac Surgery.

Thierry Mesana, MD, PhD

President and CEO, University of Ottawa Heart Institute;

Cardiac Surgeon, University of Ottawa Heart Institute;

Professor, Cardiac Surgery, University of Ottawa.


19

Dr. Nery is a cardiac electrophysiologist specialized in the treatment of complex cardiac arrhythmias.

His major clinical interest is radio-frequency ablation for atrial fi brillation and ventricular tachycardia. He

has a particular interest in the diagnosis and management of patients with cardiac sarcoidosis.

Dr. Nery’s research interests are directly linked to his clinical expertise. He is actively involved in research

studies assessing innovative catheter ablation strategies for the treatment of atrial fi brillation and

ventricular tachycardia.

Pablo Nery, MD

Staff Cardiac Electrophysiologist, University of Ottawa Heart Institute;

Associate Professor, Faculty of Medicine, University of Ottawa

Dr. Nattel received his MD in 1974, Internal Medicine and Clinical Pharmacology training between 1974

and 1978 (McGill), and Cardiology clinical and research training (Indiana University and University of

Pennsylvania 1978-1981) before joining the faculty at McGill in 1981. In 1987, he transferred to the

Montreal Heart Institute, where he directed the Research Center between 1990 and 2004. He is presently

Paul-David Chair in Cardiovascular Electrophysiology at the University of Montreal. He is Editor in Chief of

the Canadian Journal of Cardiology, Associate Editor of Heart Rhythm, Cardiovascular Research and Journal

of Physiology, and is on the editorial board of 12 other journals. His research focuses on clinically-relevant

mechanisms of cardiac bioelectricity, particularly atrial fi brillation, proarrhythmia, cardiac remodeling,

ion channel molecular physiology and mechanisms of drug action. His lab uses a wide range of molecular,

cellular, whole-animal and theoretical methods to gain insights into clinically-relevant basic mechanisms

and identify novel therapeutic targets.

Dr Nattel’s area of research is basic mechanisms of cardiac electrical activity and arrhythmias, with a

particular interest in cardiac ion channel function, atrial fi brillation and novel, mechanistically-based

therapeutic approaches.

Stanley Nattel, MD

Professor of Medicine and Paul-David Chair in Cardiovascular Electrophysiol-

ogy, University of Montreal;

Cardiologist and Director, Electrophysiology Research Program, Montreal

Heart Institute;

Editor-in-Chief, Canadian Journal of Cardiology


20

Dr. Ratika Parkash is an outcomes and clinical trials researcher in atrial fi brillation and cardiac implantable

electrical devices. Dr. Parkash was previously Chair of the Canadian Heart Rhythm Society Device

Committee and, as such, led research on Riata (St Jude Medical) in Canada. The retrospective survey on

Riata was accepted for publication in Heart Rhythm in 2013.

Dr. Parkash research foci include Atrial fi brillation – mechanisms of disease, clinical trials, management

strategies and Cardiac Implantable Electronic devices – device recalls, management, outcomes,

complications.

She has received the following awards and recognitions: Greg Ferrier Award, 2006 and 2013, awarded

to highest ranked Heart and Stroke Foundation of Canada Grant in Nova Scotia, Award of Merit Grand

Rounds, Department of Medicine 2011; Young Investigator Award 2006; Community of Scholars Excellence

in Research 2008; CIHR Randomized Clinical Trials Mentoring Award 2008-2010; Research grants from

CIHR, HSFC and Nova Scotia Health Research Foundation, Cardiac Arrhythmia Network (CANet).

Ratika Parkash , MD, FRCPC

Division of Cardiology (Arrhythmia), QE II Health Sciences Center;

Professor of Medicine, Dalhousie University


21

Dr. Redpath received undergraduate medical training in Glasgow, Scotland and was awarded membership

of the Royal College of Physicians & Surgeons of Glasgow (MRCP) in 2000. The work of his PhD studied

human cellular cardiac electrophysiology. He joined the Heart Institute in 2010.

Dr. Redpath’s research focuses on the prevention, detection and treatment of all arrhythmia-related

disorders with a special interest in atrial fi brillation. His research interests span from single atrial cells all

the way to population based studies and are primarily aimed at a greater understanding of arrhythmia

mechanisms, with particular focus on atrial fi brillation.

Calum Redpath, MD, PhD

Clinician-Scientist and Staff Cardiologist,


Assistant Professor, Department of Medicine,


Dr Redfearn is a cardiologist specialising in electrophysiology, the treatment of arrhythmia. His has

particular expertise in catheter ablation of complex arrhythmia. He holds a doctorate degree in Medicine

and is cross-appointed with the School of Computing and the Department of Biomedical and Molecular

Sciences. He is the Director of the Heart Rhythm Service at Kingston General Hospital.

His research interests include catheter ablation and improved non-invasive diagnostic tools through

enhanced ECG interpretation. His research lab focuses on novel algorithm development and electrogram

analysis. Clinical work includes optimal RV lead placement in CRT.

Damian Redfearn, MB ChB MD MRCPI FRCPC

Associate Professor, Department of Medicine

Department of Biomedical and Molecular Sciences,

School of Medicine, Queen’s University


22

Dr. Reed received her BA and BPHE from Queen’s University in 2005, and Master of Education in Coaching

Science (MEd CS) from the University of Victoria in 2007. She later earned her PhD in Kinesiology, with a

specialty in exercise physiology and women’s health, from The Pennsylvania State University in 2012.

In 2013, she joined the Division of Prevention and Rehabilitation at the University of Ottawa Heart

Institute as a Postdoctoral Research Fellow. In her current position as an Associate Scientist, her overall

research program focuses on the role of exercise and nutritional strategies in cardiovascular disease

prevention and rehabilitation as well as women’s health.

In 2013, Dr. Reed was awarded the Jan & Ian Craig Cardiac Prevention and Rehabilitation Endowed

Fellowship from the University of Ottawa Heart Institute. She was also awarded the Harold F. Martin

Graduate Assistant Outstanding Teaching Award (2011) and Research Fellowships (2008-2011) from the

Pennsylvania State University.

Jennifer Reed, PhD

Associate Scientist, Division of Prevention and Rehabilitation;

Director, Exercise Physiology and Cardiovascular Health Lab,


Part-Time Professor, Faculty of Health Sciences, University of Ottawa


23

Jason Roberts assumed the role of Clinical Cardiac Electrophysiologist and Assistant Professor of Medicine

at Western University in London, Ontario, Canada in August, 2015. He completed his training in cardiac

electrophysiology at the University of California, San Francisco (UCSF) during a 3 year fellowship that also

included a year of dedicated research. During this period, he obtained a Master’s Degree in Epidemiology

and Biostatistics from UCSF. He completed his Cardiology Fellowship at the University of Ottawa Heart

Institute, his Internal Medicine Residency at the University of Toronto, and Medical School at Memorial

University.

As a clinician scientist, his research centers on the genetics of cardiac arrhythmias. During his training in

Ottawa, he worked in the laboratory of Dr. Michael Gollob and studied the genetics of atrial fi brillation

and inherited arrhythmia syndromes, including the short QT syndrome. He also worked with Dr. Derek So

and Spartan Bioscience to develop a point-of-care genetic test for clopidogrel, the results of the clinical

trial being subsequently published in the Lancet. In London, his research program is focused on all aspects

of arrhythmia genetics with a particular emphasis on gene discovery and pharmacogenomic applications.

Jason D. Roberts, MD

Assistant Professor of Medicine

Schulich School of Medicine, Western University;

Cardiac Arrhythmia Service, London Health Sciences Centre


24

Dr. Allan Skanes is currently the Director of the Electrophysiology Laboratory at the London Health

Sciences Centre, University Hospital, London, Ontario, Canada, and an Associate Professor of Medicine at

Western University.

He received his medical degree in 1990 from the University of Toronto where he also completed his

Internal Medicine training. He completed his Cardiology and Electrophysiology training at the University

of Ottawa Heart Institute before a research fellowship in Syracuse New York, investigating the underlying

mechanisms of arrhythmia, especially atrial fi brillation.

The Electrophysiology Laboratory, a busy interventional program with an active and productive research

program, is a current clinical user of state of the art imaging and navigation technologies. Dr. Skanes,

Director, is an experienced electrophysiologist and clinician scientist with a specifi c interest in non-

pharmacologic therapy for arrhythmia, remote and non-fl uoroscopic catheter navigation and catheter

ablation of cardiac arrhythmia. He is uniquely skilled to evaluate clinical utility of imaging and tracking

technologies, image-modality compatible tools, as well as fusion of device representations with maps of

anatomy and function.

Most recently, he co-chaired the 2010 Canadian Cardiovascular Society management guidelines for atrial

fi brillation as well as the 2012 Focused Update. He is actively researching novel non-fl uoroscopic catheter

navigation technologies in animal models, as well as human studies. His research contributes clinical

relevance and applicability to development of navigation and guiding technologies. It also provides

unique experience and skill set, as well as environment for further translational development to human

studies.

He has published 144 peer-reviewed papers and 10 book chapters.

Allan Skanes, MD, FRCPC

Professor, Department of Medicine

Schulich School of Medicine & Dentistry

The University of Western Ontario


25

Dr. Anthony Tang is Professor of Medicine at Western University and Adjunct Professor of Medicine in the

Faculty of Medicine at the University of Ottawa. Dr. Tang is presently Staff Electrophysiologist, Division

of Cardiology, London Health Science Centre and Chair of Cardiovascular Population Health. He obtained

his MD from the University of Toronto and his clinical training in Internal Medicine and Cardiology

at the University of Ottawa. Dr. Tang obtained a Heart and Stroke Research Fellowship to receive

electrophysiology research training at Duke University Medical Centre. He is member of the Ontario

Medical Association, American College of Cardiology (Fellow), Canadian Cardiovascular Society, Heart

Rhythm Society (Fellow), and American Heart Association.

Dr. Tang’s clinical and research expertise is on the diagnosis and treatment of patients with cardiac

arrhythmia, particularly in heart failure patients. He has conducted multi-national, multicentre clinical

trials in the last 15 years. The research on the addition of CRT to Implantable Cardioverter Defi brillator

(ICD) and medical therapy demonstrated a reduction of total mortality and hospitalization for Heart

Failure (HF) in ambulatory heart failure patients. (NEJM 2010;363(25):2385-95). This study results

changed the treatment strategy of heart failure patients with compromized LV function and electrical

dyssynchrony. Dr. Tang currently has two CIHR grants to conduct research that examines treatment

options for patients in atrial fi brillation with heart failure. Currently, he is the Scientifi c Director for the

Canadian Arrhythmia Network (CANet), which is funded by the Network of Excellence (NCE) from 2015-20.

Dr. Tang is an internationally renowned researcher, has been an invited speaker at national and

international meetings, and is a peer reviewer for scientifi c journals, as well as grant reviewer for Heart

and Stroke and Canadian Institute of Health Research. His publication record includes over 140 peer

reviewed papers, 5 book chapters and over 270 abstracts.

Anthony Tang, MD, FRCPC

Professor, Department of Medicine

Schulich School of Medicine & Dentistry

The University of Western Ontario


26

Dr. Atul Verma received his MD degree from the University of Toronto and completed his residency in

internal medicine and cardiology there as well. He is a fellow of the Royal College of Physicians and

Surgeons of Canada in both internal medicine and cardiology. He has also been certifi ed by the American

Board of Internal Medicine in cardiovascular medicine & cardiac electrophysiology. He is currently an

assistant professor with McGill University.

Dr. Verma specializes in cardiac electrophysiology, with practice in ablation techniques, percutaneous

biventricular and basic device implantation, and in the diagnosis and management of cardiac arrhythmia

and device problems. In particular, Dr. Verma trained at the Cleveland Clinic in the ablation of complex

rhythm disorders such as atrial fi brillation and ventricular tachycardia. His research interests and activities

include the evaluation of novel catheter-based technologies and cardiac imaging techniques, and in

clinical database research and clinical trial design, with a current focus on comparing diff erent catheter-

based ablation techniques for arrhythmia control.

He has authored or co-authored over 120 articles and abstracts on electrophysiology issues, ablation,

and arrhythmia for such journals as the New England Journal of Medicine, Circulation, The Journal of the

American College of Cardiology, Heart, The Journal of Cardiovascular Electrophysiology, The American

Journal of Cardiology, and The Canadian Journal of Cardiology. Dr. Verma has received many honors and

awards during his career including being a Heart and Stroke Foundation of Canada Research Fellowship

awardee (2003-05), which is a peer-reviewed award for two years of funding for electrophysiology

research.

Dr. Verma has helped draft several national and international guidelines including the CCS Atrial

fi brillation guidelines.

Atul Verma, MD, FRCPC

Director, Heart Rhythm Program, Southlake Regional Health Centre;

Assistant Professor, Division of Cardiology, University of Toronto


27

Faculty Biographies (TOHS & EOCS)

Dr. Kirkwood F. Adams Jr., is Associate Professor of Medicine and Radiology in the Division of Cardiology,

University of North Carolina at Chapel Hill, where he founded and for many years directed the UNC Heart

Failure Program and served as the fi rst transplant cardiologist for two decades, helping to establish this

treatment at UNC.

Dr. Adams has been involved in more than 130 completed grant- and industry-funded research projects,

and he is currently leading or participating in fi ve drug development trials, several registry and database

studies, and continues to be involved in NIH/NHLBI-funded trials. Dr. Adams is the principal investigator

for the national multicenter database group, UNITE-HF, which focuses on registries of patients with heart

failure. He has published more than 175 manuscripts in refereed journals, a number of book chapters and

monographs, and more than 150 abstracts.

Dr. Adams served as chair of the Guidelines/Clinical Positions Committee of the Heart Failure Society of

America from 1996 to 2006 and is a past member of the Executive Council of this society. In addition

to drug development for acute and chronic heart failure, his current research interests are heavily

focused on personalized medicine with ongoing projects related to novel biomarkers for heart failure,

pharmacogenomics of heart failure therapeutics, and biomarker guided therapy for improving outcomes

in CHF. He is very actively involved on the Executive Committee for the NHLBI sponsored trial of NTproBNP

guided therapy known as the GUIDE-IT Trial.

Kirkwood Adams, MD

Associate Professor of Medicine and Radiology,

University of North Carolina at Chapel Hill


28

Dr. Rob Beanlands is the Chief and Vered Chair of the Division of Cardiology at the University of Ottawa

Heart Institute. He received his MD from the University of Ottawa in 1983 (gold medalist). He is an

international leader in cardiovascular nuclear imaging and the founding Director of the Heart Institute’s

National Cardiac PET Centre, the only PET facility in Canada dedicated to cardiovascular disease. He

is a Career Investigator supported by the Heart and Stroke Foundation and holds the Tier 1 Chair in

Cardiovascular Imaging Research (uOttawa). His research focus on the heart’s metabolism, fl ow and

cellular function has led to pioneering translational work that has impacted the understanding of disease

mechanisms, applications in patient care, health policy and guidelines in imaging. He has led several

multicentre imaging research initiatives [PARR2, IMAGE-HF, CADRE Registry and is a Co-PI for the Canadian

Atherosclerotic Imaging Network (CAIN)]. He has more than 225 peer reviewed publications in this

fi eld. He has served on several committees/advisory boards for government, industry and professional

organizations impacting healthcare policies and practice guidelines and serves as an Associate Editor

for the Canadian Journal of Cardiology and the Journal of Nuclear Cardiology. He is a Professor in the

Faculty of Medicine, Department of Radiology and Department of Cellular and Molecular Medicine at

the University of Ottawa. Dr. Beanlands is past-president of the Canadian Nuclear Cardiology Society,

past Ontario Governor for the American College of Cardiology and was the Scientifi c Program Chair and

Annual Meeting Chair for the Canadian Cardiovascular Society. He is also the chair of the Heart and Stroke

Foundation Scientifi c Review Committee, Treasurer of the American Society of Nuclear Cardiology and Co-

Chair of the International Congress on Nuclear Cardiology and CT imaging. Recent Awards include Queen

Elizabeth II Diamond Jubilee Medal (2012) for Contributions to Canada, Hermann Blumgart Research

Achievement Award for the Society of Nuclear Medicine (2013) and Canadian Cardiovascular Society

Research Achievement Award (2015).

Robert Beanlands, MD

Vered Chair and Chief of Cardiology,

Director, National Cardiac PET Centre,

Director, Molecular Function and Imaging Program,

Clinician Scientist; University of Ottawa Heart Institute;

Professor, Division of Cardiology, Department of Medicine,

Professor, Department of Radiology (Cross-Appointment),

Professor, Department of Cellular and Molecular Medicine

(Cross-Appointment), University of Ottawa Faculty of Medicine Research

Chair Award (Tier 1) in Cardiovascular Disease, University of Ottawa


29

Dr. Boodhwani earned a BSc with High Distinction from the University of Toronto in 1997 and a medical

degree from the University of Western Ontario in London, Ontario, in 2001. These were followed by a

residency in cardiac surgery at the Heart Institute in 2004. In 2006, he served as a research fellow in

cardiothoracic surgery at Beth Israel Deaconess Medical Center in Boston and earned a Masters in Medical

Sciences from Harvard Medical School.

Dr. Boodhwani has won numerous distinctions and awards. He has served his profession in Trinidad and

Pakistan and has been chair of the Aga Khan Health Board for Ottawa’s Medical Advisory Service.

Dr. Boodhwani’s interests include issues in complex coronary revascularization procedures and arterial

grafting, the polymer-based delivery of endothelial progenitor cells for myocardial regeneration,

cardiopulmonary bypass practices and clinical trials, neurocognitive outcomes following cardiac surgery,

coronary physiology and pharmacology, and the eff ect of diabetes, hypercholesterolemia, and endothelial

function on myocardial angiogenesis.

Munir Boodhwani, MD

Cardiac Surgeon,


Assistant Professor,



30

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in human

and rodent echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function. His

work has been recognized evident by winning the “Young Investigator of the Year Award” in 2012 by the

Canadian Cardiovascular Society an Early Researcher Award in 2014, a CIHR New Investigator award in

2014 and the SC Verma Young Investigator Award in 2015.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where

he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular

matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon

translating discoveries into therapies in humans. He is the Director of the Krembil Stem Cell Facility at St.

Michael’s Hospital and uses stem cell based therapies to improve cardiac and renal dysfunction as a result

of diabetes. He collaborates extensively not only locally in Toronto but also nationally and internationally

– with research support from the HSF of Canada, CIHR and CFI along with signifi cant research support

from the pharmaceutical industry.

Kim Connelly, PhD

Director, Krembil Stem Cell Facility, St. Michael’s Hospital;

Staff Cardiologist, St. Michael’s Hospital;

Consultant Cardiologist, Sunnybrook Health Science Centre


31

Dr. Dwivedi completed his MD from the University of Delhi, India, in 1998 and his PhD from the University

of Manchester, England, three years later. He then secured one of the most prestigious clinical lectureships

in the United Kingdom, the National Institute of Health Research Clinical Lectureship at the University of

Birmingham, and was awarded the Certifi cate of Completion of Specialist Training in Cardiology.

He moved to the University of Ottawa Heart Institute in 2011 to obtain further experience in cardiac CT,

SPECT and PET imaging techniques, and was awarded the prestigious CIHR Banting Fellowship. He has

obtained training and accreditation in echocardiography, cardiac MRI, cardiac CT, PET and SPECT. He joined

the staff of the Heart Institute in 2013.

Dr. Dwivedi’s clinical and research interests centre on cardiac imaging, with special emphasis on

infl ammation as the cause of atherosclerosis, heart failure and cardiomyopathy, and application of

myocardial contrast echocardiography.

Girish Dwivedi, MD, PhD

Cardiologist, University of Ottawa Heart Institute;

Assistant Professor, University of Ottawa


32

Dr. Huang is the Chief and Chair of the Division of Geriatrics. He comes to us from McGill University Health

Centre (MUHC), Montreal, Quebec where he was a former director, Division of Geriatric Medicine and

program director, McGill postgrad residency program in Geriatric Medicine

Research/focus

Health services research: Optimal pharmacotherapy for older adults. Health informatics.

Medical education: time & motion studies. Interprofessional teams.

Awards and Recognition

2003 Qualcomm CDMA-A-List award for Impact, non-profi t category. For the MOXXI project & wireless

prescribing.

2006 Prix J.-Armand-Bombardier – Innovation. (ACFAS – Association canadienne-française pour

l’avancement des sciences)

Allen Huang, MDCM, FRCPC, FACP, AGSF

Chief & Chair, Division of Geriatric Medicine,

University of Ottawa and The Ottawa Hospital;

Associate Professor of Medicine, Faculty of Medicine, University of Ottawa;

Adjunct Professor, Faculty of Medicine, McGill University

Dr. Le May is an interventional Cardiologist and Professor of Medicine at the University of Ottawa Heart

Institute, as well as the Director of the HOHI Regional STEMI Program.

His primary research focus is on developing novel strategies for the management of acute myocardial

infarction.

Dr. Le May has been the recipient of numerous awards throughout his career, including the Heart

Institute’s inaugural Global Achievement Award in Clinical Leadership in 2015, the Lumen Global

Achievement Award presented by HRH Princess Chulabhorn Walailak of Thailand in 2014, the Top

Achievement CIHR Award in 2009 and was named the Heart Institute Clinical Science Investigator of the Year

in 2008.

Michel Le May, MD, FRCPC

Interventional Cardiologist,


Professor of Medicine,



33

Dr. Alan S. Maisel graduated from the University of Michigan Medical School, received his internal

medicine training at Michael Reese Hospital in Chicago, where he was chief resident, and completed a

cardiology fellowship at the University of California, San Diego.

Dr. Maisel is a Professor of Medicine at the University of California, San Diego (UCSD). He is the Director

of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla,

California. Dr. Maisel is active on the faculty at UCSD where he has won numerous teaching awards. He

just completed a ten-year stint as Associate Editor of the Journal of the American College Cardiology

Dr Maisel is considered one of the world’s experts on cardiac biomarkers and has over 400 scientifi c

publications. He has authored several ground-breaking manuscripts that have paved the way for

development of diagnostic tools for patients with congestive heart failure. In particular, he was the

leading investigator on studies that brought the use of BNP into clinical practice. He has been lead

investigator on seven multicentre biomarker trials.

His recent work on cardiac biomarkers has led to a connection between diet, cardiovascular disease and

breast cancer, and currently works on two biomarkers that predict the development of breast cancer. He

recently co-founded the UCSD Biomarker Research Center, which among other things make data and a

statistician available for research by residents and fellows.

Dr Maisel is also a writer of medical fi ction. His fi rst novel, Bedside Manners was optioned to Warner

Brothers. His second novel, Brain Chicane, is about a young and idealistic physician working at the premier

multiple-organ transplant hospital in Chicago where he investigates overdose cases that are not totally

kosher. He is also co-founder of a mitochondrial drug company and a biomarker discovery company.

He is founder of My Life Diagnostics. He is a co-founder of Aceptiscope. He is the primary care-giver for

fi ve children and gave up on sleep fi ve years ago.

Alan S. Maisel, MD

Professor of Medicine , University of California, San Diego

Director, Coronary Care Unit and Heart Failure Program, Veterans Aff airs San

Diego Healthcare System


34

Dr. G.B. John Mancini is a tenured Professor of Medicine at the University of British Columbia, and

directs an imaging-based research program (Cardiovascular Imaging Research Core Laboratory, CIRCL)

that includes facilities for quantitative coronary angiography, ultrasound analysis (coronaries, carotids

and brachial artery for atherosclerosis and endothelial function assessments) and cardiac computed

tomography analysis. Dr. Mancini remains in active practice as a staff physician in the Vancouver Hospital

Cardiology Outpatient Clinic and the Cardiac Computed Tomography Program, as well as the St. Paul’s

Hospital Healthy Heart Prevention Program/Lipid Clinic.

Dr. Mancini received his MD degree from the University of Toronto, completed his residency at Toronto

General Hospital and was a Cardiology and Research Fellow at the University of California at San Diego.

After a year as Clinical Assistant Professor at U.C. San Diego, he joined the faculty of the University of

Michigan, where he became Associate Chief of Cardiology and Chief of the V.A. Section of Cardiology in

1987. He was Chair of Medicine at the University of British Columbia from 1992 to 2002. He is a Fellow of

the American College of Cardiology, Governor of the American College of Cardiology (British Columbia) and

a member of the Circulation Council of the American Heart Association; he is also a member of numerous

other professional associations in the United States and Canada. Dr. Mancini is a Past President of the

Canadian Society for Clinical Investigation and current President of the Medical/Allied Staff of Vancouver

Hospital. He has published over 250 journal articles, abstracts, books and book chapters. He serves as a

reviewer for many journals, and is currently a member of the editorial boards of the American Journal of

Cardiology, the Canadian Journal of Cardiology and the International Journal of Cardiac Imaging.

Dr. Mancini is currently Coordinating Investigator for the Cardiovascular Imaging Research Core Laboratory

for numerous multi-centred trials. His areas of special interest include digital angiography, quantitative

coronary angiography, quantitative intravascular ultrasound, quantitative carotid ultrasound, cardiac

computed tomography, coronary fl ow reserve/fractional fl ow reserve, endothelial dysfunction, primary

and secondary CV risk reduction and regression of atherosclerosis.

G.B. John Mancini, MD

Cardiology, Vancouver General Hospital;

Professor of Medicine, University of British Columbia;

Director, Cardiovascular Imaging Research Core Laboratory-CIRCL


35

Dr. McPherson received her PhD from the University of London, in England, and her MD from the

University of Toronto, where she graduated magna cum laude in 1984. She completed subspecialty

training in Internal Medicine and Endocrinology and Metabolism at the University of Toronto. She held

academic positions at the University of Toronto and McGill University before joining the University of

Ottawa Heart Institute in 1992.

Dr. McPherson is a key opinion leader in Canada in the area of clinical lipidology and cardiovascular risk

reduction. Dr. McPherson has been an author on the several renditions of the Canadian Cardiovascular

Society Position Statement on the Diagnosis and Treatment of Dyslipidemia and Prevention of

Cardiovascular Disease and is a strong advocate of strategies for the primary and secondary prevention

of cardiovascular disease. Dr. McPherson is Associate Editor of Arteriosclerosis, Thrombosis, and Vascular

Biology and is a member on the Editorial Boards of the Canadian Journal of Cardiology, Journal of Lipid

Research, and Circulation – Cardiovascular Genetics.

Dr. McPherson’s research is funded by the Canadian Institutes of Health Research and the Heart and Stroke

Foundation of Canada. She has published over 190 manuscripts in peer-reviewed journals. She is a lead

investigator of the CARDIoGRAM+C4D consortium; her other global partnerships are extensive,including

GIANT, MAGIC, Global Lipids, NHLBI ESP, Diogenes and other networks. She has been a keynote speaker at

a number of international conferences, including the American Heart Association ATVB meeting, Gordon

Conference, International Society of Atherosclerosis and Keystone meeting. Dr. McPherson currently holds

the Merck Frosst Canada Chair in Atherosclerosis. Dr. McPherson’s achievements have been recognized

with a number of awards, including the The Journal of Lipid Research Lectureship Award, ISA XVI, 2012,

AHA Council on Arteriosclerosis, Thrombosis & Vascular Biology. Arteriosclerosis Special Recognition

Award, 2011, International Atherosclerosis Symposium XV 2009: Outstanding Achievement Award. She

was elected a fellow of the Royal Society of Canada in 2014.

Dr. McPherson is a leader in cardiovascular genetics, having led the discovery of the 9p21 genetic risk

factor for heart disease in 2007. Dr. McPherson’s research is centered on the discovery and functional

analysis of genetic variants linked to cardiovascular disease and its metabolic precedents, including lipid

traits and obesity.

Ruth McPherson, MD, PhD

Merck Frosst Canada Chair in Atherosclerosis Research;

Director, Ruddy Canadian Cardiovascular Genetics Centre;

Director, Atherogenomics Laboratory and Lipid Clinic,


Professor, Departments of Medicine and Biochemistry,



36

Dr. Reid obtained his PhD in Health Studies at the University of Waterloo in 1997 following an MBA in

Marketing from the University of Ottawa in 1990. He is one of Canada’s leading health behavior change

experts, particularly concerning smoking cessation, physical activity promotion, dietary change and

cardiovascular rehabilitation.

Dr. Reid’s research is funded by the Heart and Stroke Foundation of Canada, the National Cancer Institute

of Canada, the Canadian Tobacco Control Research Initiative, the Ontario Ministry of Health Promotion, the

Change Foundation, and Health Canada.

He is the Canadian Association of Cardiac Rehabilitation 20th Anniversary Research Leadership Award

recipient. He was also awarded the Investigator of the Year (Clinical Science) award in 2011. In addition,

he is a past recipient of the Heart and Stroke Foundation of Canada’s New Investigator Award. In 2009,

he delivered the prestigious 17th Annual Terry Kavanagh Lecture at the Canadian Association of Cardiac

Rehabilitation symposium. In 2006, he was awarded the James Hogg Award from the Canadian Institutes

of Health Research Institute for Circulatory and Respiratory Health for his contributions to clinical and

population health research.

The overall aim of Dr. Reid’s research is to improve the quality and effi ciency of chronic disease prevention

and management programs. Over the past 10 years, his research group has focused on three main themes:

1) developing systematic approaches to smoking cessation in clinical practice settings; 2) promoting

exercise and physical activity in patients with heart disease; and 3) examining the eff ectiveness and

cost-effi ciency of diff erent models of delivering primary and secondary prevention services. More recently,

the group has taken on the challenge of how best to reduce risk and prevent heart disease in the family

members of patients with diagnosed heart disease.

Robert Reid, PhD, MBA

Deputy Chief, Division of Prevention and Rehabilitation,


Professor, Faculty of Medicine,



37

Dr. Chris Simpson is Professor of Medicine and Chief of Cardiology at Queen’s University as well as the

Medical Director of the Cardiac Program at Kingston General Hospital / Hotel Dieu Hospital. In 2015, Dr.

Simpson was elected to fellowship in the Canadian Academy of Health Sciences. He is the Past President of

the Canadian Medical Association (CMA).

Dr. Simpson’s primary professional interest is health policy – particularly access to care. He serves as

the Chair of the Wait Time Alliance (WTA) and as Past Chair of the Canadian Cardiovascular Society’s

(CCS) Standing Committee on Health Policy and Advocacy. He was the Lead for the Southeast (Ontario)

Local Health Integration Network (LHIN) Cardiovascular Roadmap Project. He serves on the Cardiac Care

Network of Ontario board of directors, and is a past member of the CCS executive and a former governor of

the American College of Cardiology.

He served as the fi rst President of the Canadian Heart Rhythm Society and was a founding executive

member of the International Coalition of Pacing and Electrophysiology Organizations (COPE). He sits

on numerous editorial boards and advisory committees, and has chaired or been a member of several

national and international consensus conferences, including serving as co-chair of the CCS Consensus

Conference on Medical Fitness to Drive and Fly. He was President of the Canadian Medical Association in

2014-2015 and is a past recipient of the Canadian Medical Association’s Award for Young Leaders.

Dr. Simpson is an active clinician, educator and researcher. He has authored or co-authored over 350

peer-reviewed publications. His clinical and research interests include access to care, medical fi tness

to drive, referral pathway development, atrial fi brillation, sudden death in the young, and cardiac

resynchronization therapy.

Christopher S. Simpson, MD, FRCPC, FACC, FHRS, FCAHS

Professor of Medicine & Chief of Cardiology, Queen’s University;

Medical Director, Cardiac Program, Kingston General Hospital / Hotel Dieu

Hospital;

Past President, Canadian Medical Association;


38

Dr. Derek So earned his medical degree, cum laude, at the University of Toronto in 1997. He completed

residencies in Internal Medicine at McMaster University in Hamilton, Ontario, and Cardiology at

the University of Ottawa Heart Institute. He then went on to Fellowship training in Interventional

Cardiology at the University of Ottawa Heart Institute. He furthered his training with a Master’s in Clinical

Epidemiology at the Harvard School of Public Health in Cambridge, Massachusetts.

Dr. So’s research interests include: acute coronary syndromes, PCI outcomes, pharmacogenomics and

personalized anti-platelet therapy. Currently, Dr. So is leading a group of basic science and clinical

researchers in the RAPID program, studying future strategies for personalized anti-platelet therapy.

Dr. So has held grants from the Canadian Institute of Health Research (CIHR) and the Heart and Stroke

Foundation (HSF) in the fi eld of anti-platelet therapies. He currently holds a mid-career investigator

award from HSF. As part of the RAPID program, Dr. So presented the RAPID GENE study as a late breaking

trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 conference. This study has been

published in The Lancet.

Derek So, MD, FRCPC, FACC

Director, Adult Interventional Cardiology Program


Associate Professor



39

Dr. Bradley Strauss was born in Kitchener, Ontario, Canada. He obtained his MD cum laude from the

University of Toronto in 1982. He completed his Residency Training in Internal Medicine at the University

of Toronto in 1986 and then a Clinical Fellowship in Cardiology at the University of Ottawa Heart Institute

in 1988. Subsequently he was awarded a Research Fellowship from the Heart and Stroke Foundation to do

research work at the world-famous Thoraxcenter in Rotterdam, the Netherlands under the supervision of

Professor Patrick Serruys. During his time in Rotterdam, he obtained a PhD from Erasmus University for his

work on coronary stenting and the arterial response to stenting injury.

He currently is Chief of the Schulich Heart Program and Head of the Division of Cardiology at Sunnybrook

Health Sciences Centre in Toronto, Canada. He holds the Reichmann Chair in Cardiovascular Research, and

is a Professor of Medicine and Professor of Laboratory Medicine and Pathobiology at the University of

Toronto.

His main clinical activity is interventional cardiology. He is very active in both basic research (arterial

response to injury, angiogenesis) and clinical research related to interventional research and coronary

imaging. He has authored over 170 papers and 18 book chapters and serves on the Editorial Board of

5 journals. His main clinical interest is chronic total occlusions, including studies on pathophysiology,

epidemiology, imaging and development of new chronic occlusion therapies. He has founded a company,

Matrizyme Pharma, to commercialize the use of collagenase to soften the plaque in order to facilitate

guidewire crossing in chronic total occlusions. Matrizyme Pharma has recently completed a Phase 2

Clinical Trial (TOSCA-5) in 11 Canadian centers as well as sites in Israel and the Netherlands.

Bradley Strauss, MD, PhD

Senior Scientist,

Director, Interventional Cardiology Research, Sunnybrook Health Sciences

Centre;

Professor, Department of Medicine,

Professor, Laboratory Medicine and Pathobiology, University of Toronto;

Reichmann Chair, Cardiovascular Sciences,

Sunnybrook Health Sciences Centre and University of Toronto


40

Dr. Udell is a Cardiologist and clinician-scientist at Women’s College Hospital and the Peter Munk Cardiac

Centre, University Health Network and an Assistant Professor of Medicine at the University of Toronto

with expertise in observational studies, clinical trials, and health services research. His group’s work on

innovative cardiovascular risk factor identifi cation and therapy has led to: clinical trial and outcomes

publications in the New England Journal of Medicine, JAMA, JACC, and Lancet Diabetes and Endocrinology;

alterations in national practice guidelines; and changes by the FDA in the label of saxagliptin. Utilizing

the administrative health care databases, registries, and clinical trial populations at his disposal, Dr. Udell

studies the cardiovascular benefi ts and risks of new diabetes and antiplatelet therapies and novel risk

factors, including infl uenza infection. Dr. Udell is a Co-Principal Investigator of the 9300-patient INVESTED

randomized controlled trial, which is investigating the cardiovascular benefi t of high-dose versus

standard-dose infl uenza vaccination. He is a regular Checkup Panel member on CBC TV’s The National

news broadcast discussing timely health topics and the recipient of multiple awards, including a CIHR

Health Services and Policy Research Rising Star Award (2014), a Heart and Stroke Foundation of Canada

National New Investigator/Ontario Clinician Scientist (Phase I) Award (2016), and an Ontario Ministry of

Research and Innovation Early Researcher Award (2016).

Jacob A. Udell, MD, MPH, FRCPC

Cardiovascular Division, Women’s College Hosptial,

Peter Munk Cardiac Centre, Toronto General Hospital

University of Toronto


41

Bernard Zinman completed his medical degree at McGill University, Montreal, Quebec, Canada, and

received further training in endocrinology at the University of Toronto.

Dr Zinman is involved with diabetes care and research at both national and international levels.

His main research interests include the long-term complications of diabetes, the development of new

therapies for type 1 and type 2 diabetes, diabetes in aboriginal communities, and studies directed at the

prevention of diabetes. He is the recipient of numerous awards including the Charles H. Best Medal for

Distinguished Service in the Cause of Diabetes (awarded to the Diabetes Control and Complications Trial

Investigators), the American Diabetes Association Outstanding Physician Clinician Award, the Novartis

Prize for Diabetes, the Lifetime Achievement Award from the Canadian Diabetes Association and notably

Dr Zinman was appointed to the Order of Canada, in recognition of his achievements in diabetes patient

care and research. He is Vice Chair for the Diabetes Control and Complications Trial/Epidemiology of

Diabetes Interventions and Complications (DCCT/EDIC) study. Dr Zinman has authored more than 500

publications in national and international journals, and over 60 book chapters and editorials.

Bernard Zinman, CM MD FRCPC FACP

Director, Leadership Sinai Centre for Diabetes;

Sam and Judy Pencer Family Chair in Diabetes,

Mount Sinai Hospital and University of Toronto;

Professor of Medicine, University of Toronto;

Senior Scientist, Lunenfeld-Tanenbaum Research Institute,

Mount Sinai Hospital


42

Faculty Disclosures (OHRC)

Name Company Disclosure Details

Peter Backx

David Birnie Bayer, Boehring-Ingelheim Clinical Trial

Hugh Calkins Boehringer-Ingleheim PI Clinical Trial

Medtronic Consultant

Jeff Healey

José Jalife Topera-Abbott Labs Consult on mechanism of atrial

fi brilation

Medtronic, Inc Research Grants

Gregory Lip Bayer, Janssen, Astellas,

Merck,Sanofi ,BMS/Pfi zer, Biotronik,

Medtronic, Portola, Boehringer-In-

gelheim, Microlife and Daiichi-Sankyo

Consultant

Bayer,BMS/Pfi zer,Medtronic, Boehringer-

Ingelheim, Microlife, Roche and Daiichi-

Sankyo

Payment from Comm Org

Peter Liu Novartis, Roche, Amgen, Pfi zer, Merck,

Janssen

Advisory board

Servier, Roche Diagnostics, Novartis Grants

Stanley Nattel Omeicos, Merck, Aptose Pharm Research Contract, Consulting

Ratika Parkash St. Jude Medical, Pfi zer, Bayer, Medtronic Research Grants

St. Jude Medical, Pfi zer Clinical Trial

Damian Redfearn

Jennifer Reed

Jason Roberts No disclosures

Allan Skanes Bayer, Pfi zer, Boehringer-Ingelheim Honoraria (speaking)

Anthony Tang Medtronic Research Grant

Medtronic, Jude Medical, Sorin, Arca

Biopharm, Boehringer-Ingelheim

Clinical Trial

Atul Verma Biosense, Medtronic Advisory Board

Bayer, Biosense, Medtronic Compensation, Grant

Medtronic, St Jude Medical Clinical Trial


43

Faculty Disclosures (TOHS & EOCS)

Name Company Disclosure Details

Kirkwood Adams Novartis, Covis, AMGEN, Relypsa Expert Counsel

Novartis, AMGEN, Covis, Roche Grant

Novartis, AMGEN, Roche Clinical Trial

Robert Beanlands GE Healthcare, Lantheus, Medical

Image, Jubilant DRAXImage

Grant/Honorarium

Munir Boodhwani

Hugh Calkins Boehringer-Ingelheim PI Clinical Trial

Medtronic Consultant

Kim Connelly Astra Zeneca, B-I,Merck, Servier,

Janssen

Advisory Board or Equivalent

Astra Zeneca, B-I,Merck, Servier Grants/Honorarium

B-I Patent

B-I, Servier Clinical Trial

Girish Dwivedi No disclosures

Michael Farkouh Amgen, Servier Grant / Honorarium

Michael Froeschl No disclosures

Allen Huang No disclosures

Michel Le May No disclosures

Peter Liu See Faculty Disclosures (OHRC 2016)

Alan Maisel Critcal DX, AdrenoMed Advisory Board or equivalent:

Modest Stipend

Alere, Abbott, Critical DX, Siemens received payment for talks

Alere, Abbott, Critical DX, Siemens Grants/Honorarium

Novartis Clinical Trial

John Mancini Amgen, Sanofi , Servier Advisory Board or equivalent: Mod-

est Stipend

Amgen, Sanofi , Servier Speakers Bureau: Modest

Amgen, Sanofi , Servier received payment for talks

Amgen, Merck Grants/Honorarium: Modest

NIH Ischemia Clinical Trial- medical vs revascular-

ization therapy, core CCTA analysis


44

Ruth McPherson Sanofi , Amgen Advisory Board or equivalent

Sanofi , Amgen Speakers Bureau

Pfi zer, Sanofi Clinical Trial - Studies on safety and

effi cacy of PCSK9 inhibitors

Thierry Mesana No disclosures

Robert Reid Pfi zer Speaker Bureau re: smoking

Pfi zer, Johnson and Johnson Grants

Christopher Simpson National Speakers Bureau

Derek So Eli-Lilly, Spartan Bioscience Inc Physician Initiated Grant

Bradley Strauss Matrizyme Pharma Founder, member of Board of

Directors; Salary; hold Patent (col-

lagenase patents for chronic total

occlusion); Shares; Clinical Trial

Sheldon Tobe

Jacob Udell AMGEN, Janssen, Sanofi -Pasteur Advisory Board

Merck Speakers Bureau

Servier, Astra Zeneca Grant

Novartis Clinical Trial

Bernard Zinman Astra Zeneca, Boehringer-Ingelheim,

Merck (feel like there is one that got

cut off )

Advisory Board or Equivalent

Astra Zeneca, Boehringer-Ingelheim,

Novo Nordsk

Research Grants to Institution

Novo Nordsk, Boehringer-Ingelheim,

Astra Zeneca

CVD outcome Trials


45

Accreditation

This event is an Accredited Group Learning Activity (Section 1) as defi ned by the Maintenance of Certifi cation program of the Royal College of Physicians and Surgeons of Canada for 19.50 hours.

Cette activité est une activité de formation collective agréée aux termes de la Section 1 du programme de Maintien du certifi cat du Collège royal des médecins et chirurgiens du Canada pour 19,50 heures.

This program has also been accredited by the College of Family Physicians of Canada, for up to 19.50 Mainpro-M1 hours. This program has been reviewed and approved by the University of Ottawa, Offi ce of Continuing Professional Development.

Ce programme répond aux critères d’agrément du Collège des médecins de famille du Canada accorde jusqu’à 19,50 heures Mainpro-M1. Ce programme a été révisé et approuvé par le Bureau de formation professionnelle continue de l’Université d’Ottawa.

AMA designation statement:

Through an agreement between the Royal College of Physicians and Sur-geons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Informa-tion on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

En vertu d’une entente conclue entre le Collège royal des médecins et chiru-rgiens du Canada et l’American Medical Association, les médecins peuvent convertir les crédits obtenus au titre du programme de MDC du Collège royal en crédits de catégorie 1 de l’AMA PRAMC. Vous trouverez l’information sur le processus de conversion des crédits du programme de MDC du Collège royal en crédits de l’AMA à l’adresse www.ama-assn.org/go/internationalcme.


46

Notes

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________

____________________________________


i


ii

4th

ANNUAL OTTAWA HEART

oottawa heart conferences 2016ttawa heart …...ottawa heart conferences 2016 i 4th annual ottawa...

Documents